Author Affiliations: Department of Dermatology (Drs Evans, Rook, and Kim) and Department of Medicine, Divisions of Hematology/Oncology (Dr Loren) and Cardiovascular Medicine (Dr Glassberg), The Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Interferons are natural polypeptides used as biologic therapy in patients with cutaneous T-cell lymphoma (CTCL), melanoma, and hepatitis C. In CTCL, interferon alfa enhances the host's cytotoxic T-cell response through upregulation of CD8+ and natural killer cell activity and downregulation of the helper T cell type 2 cytokine profile.1,2
Evans KG, Loren AW, Rook AH, Kim EJ, Glassberg HL. Congestive Heart Failure in a Patient With Cutaneous T-Cell Lymphoma Treated With Low-Dose Interferon Alfa-2b. Arch Dermatol. 2011;147(9):1123-1124. doi:10.1001/archdermatol.2011.246